Ousted FDA vaccine chief Vinay Prasad is returning to the agency

WASHINGTON (AP) — A Food and Drug Administration official is getting his job back as the agency’s top vaccine regulator, less than two weeks after he was pressured to step down at the urging of biotech executives, patient groups and conservative allies of President Donald Trump.

Dr. Vinay Prasad is resuming leadership of the FDA center that regulates vaccines and biotech therapies, a spokesperson for the Department of Health and Human Services said in a statement Monday.

Related Articles


New Medicaid federal work requirements mean less leeway for states


Stigma still keeps police from seeking mental health care, study finds


Protect your dog against Lyme disease


When hospitals buy physician practices, prices go up


Deep staff cuts at a little-known federal agency pose trouble for droves of local health programs

Prasad left the agency late last month after drawing ire of right-wing activists, including Laura Loomer, because of his past statements criticizing Trump.

A longtime a critic of FDA’s standards for approving medicines, Prasad briefly ordered the maker of a gene therapy for Duchenne’s muscular dystrophy to halt shipments after two patient deaths. But that action triggered pushback from the families of boys with the fatal condition and libertarian supporters of increased access to experimental medicines.

Prasad’s decision to pause the therapy was criticized by The Wall Street Journal editorial board, former Republican Sen. Rick Santorum and others. The FDA swiftly reversed its decision suspending the therapy’s use.

Loomer posted online that Prasad was “a progressive leftist saboteur,” noting his history of praising liberal independent Sen. Bernie Sanders.

But Prasad has had the backing of FDA Commissioner Marty Makary and health secretary Robert F. Kennedy Jr., who have both called for scrutinizing the use of COVID-19 vaccines. Under Prasad, the FDA restricted the approval of two new COVID-19 shots from vaccine makers Novavax and Moderna and set stricter testing requirements for future approvals.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Leave a Reply

Your email address will not be published.

Previous post Ousted FDA vaccine chief Vinay Prasad is returning to the agency
Next post Celtics cut another member of 2024-25 team, can now sign final draft pick